Janus Henderson Group PLC Acquires 83,568 Shares of argenex SE $ARGX

Janus Henderson Group PLC boosted its stake in shares of argenex SE (NASDAQ:ARGX) by 3.4% during the 1st quarter, HoldingsChannel reports. The fund owned 2,541,732 shares of the company’s stock after purchasing an additional 83,568 shares during the period. argenex accounts for about 0.9% of Janus Henderson Group PLC’s holdings, making the stock its 14th largest position. Janus Henderson Group PLC’s holdings in argenex were worth $1,847,592,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Cim LLC lifted its stake in shares of argenex by 5.0% in the 1st quarter. Cim LLC now owns 2,769 shares of the company’s stock valued at $2,022,000 after purchasing an additional 133 shares during the last quarter. Oddo BHF Asset Management Sas increased its position in shares of argenex by 6.5% during the 1st quarter. Oddo BHF Asset Management Sas now owns 25,009 shares of the company’s stock valued at $18,263,000 after purchasing an additional 1,536 shares during the last quarter. Amundi increased its position in shares of argenex by 44.6% during the 1st quarter. Amundi now owns 61,433 shares of the company’s stock valued at $44,861,000 after purchasing an additional 18,948 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of argenex by 25.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 258 shares of the company’s stock valued at $188,000 after purchasing an additional 53 shares during the last quarter. Finally, Eagle Health Investments LP raised its holdings in argenex by 21.7% during the 1st quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock valued at $55,744,000 after buying an additional 13,606 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Stock Up 1.2%

ARGX stock opened at $882.56 on Thursday. argenex SE has a twelve month low of $596.01 and a twelve month high of $953.58. The firm has a market cap of $55.21 billion, a price-to-earnings ratio of 33.89, a PEG ratio of 1.13 and a beta of 0.45. The business’s fifty day simple moving average is $873.58 and its two-hundred day simple moving average is $816.78.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. Research analysts expect that argenex SE will post 27.38 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ARGX. Citigroup lifted their price objective on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Guggenheim increased their target price on shares of argenex from $1,135.00 to $1,185.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Weiss Ratings lowered shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 23rd. Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Oppenheimer upped their price target on shares of argenex from $1,014.00 to $1,037.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,056.89.

Key Headlines Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Forte Biosciences acquisition expands the autoimmune pipeline: argenx agreed to acquire Forte for approximately $2.2 billion, or $77 per Forte share in cash. The transaction would add Forte’s autoimmune drug candidate to argenx’s portfolio and could strengthen its long-term growth opportunities. Argenx signs agreement to buy Forte Biosciences for $2.2bn
• Positive Sentiment: Analysts raised their targets: Wedbush lifted its price target from $1,000 to $1,050 and assigned an “Outperform” rating. A separate Seeking Alpha analysis upgraded ARGX to “Buy” with a $1,050 target, citing continued VYVGART growth, additional label expansions, at-home administration and pipeline potential. Wedbush raises argenx price target argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go
• Positive Sentiment: Long-term earnings expectations improved: HC Wainwright maintained a “Buy” rating and raised its EPS forecasts for 2026 through 2030, including increases to $34.38 for 2027, $43.50 for 2028, $53.47 for 2029 and $64.39 for 2030. The revisions indicate stronger expected VYVGART-driven growth and pipeline contributions. HC Wainwright earnings estimate changes
• Neutral Sentiment: Relative performance remains in focus: Zacks compared argenx’s year-to-date performance with Agilent Technologies and the broader medical sector, but the report did not identify a new fundamental catalyst. Is Argenx Outperforming Other Medical Stocks This Year?
• Negative Sentiment: Deal scrutiny and valuation risks: A law firm is investigating whether Forte shareholders are receiving adequate consideration and whether the sale process was appropriate. Separately, analyses suggested ARGX could be fairly valued or as much as 15% above fair value after the Forte deal, raising concerns about acquisition execution and limited near-term upside. Forte Biosciences investor alert argenx could be 15% above fair value

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.